Top Analyst Cuts Price Target For Intercept Pharmaceuticals Inc (ICPT) By 50%; Here’s Why

Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.

Alnylam Pharmaceuticals, Inc. (ALNY) Picks Up a Price Target Boost from Cowen Following Stellar Phase III Top-Line Data in FAP

Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.

Top Analyst Boosts Price Target for Aldeyra Therapeutics Inc (ALDX); Here’s Why

Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.

Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish

Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM

Myokardia Inc (MYOK) Heart Drug Very Likely to Achieve FDA Breakthrough Status: Cowen

It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back …

Genocea Biosciences Inc (GNCA) May Be Crashing, But Here’s Why Cowen Sees A Significantly Undervalued Stock

Genocea Biosciences Inc (NASDAQ:GNCA) shares were plummeting almost 15% yesterday after the biotech firm and …